SCHEMBL4495205

SCHEMBL4495205

CCC(CC)c1cc(C)n2nc(-c3ccc(OC)cc3Cl)c(C(=O)O)c2c1

nearest known ligand 0.49

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 17/20 0.49
KDM4E B2RXH2 2/20 0.39
LMNA P02545 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CDC7 O00311 1/20 0.38
DBF4 Q9UBU7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4503120 0.91 CRHR1 (0.48) CRHR1CDC7DBF4
SCHEMBL4488549 0.91 CRHR1 (0.48) CRHR1KDM4EHSD17B10CDC7DBF4
SCHEMBL4488256 0.86 CRHR1 (0.53) CRHR1
SCHEMBL4492063 0.84 CRHR1 (0.52) CRHR1
SCHEMBL4483883 0.74 CRHR1 (0.53) CRHR1HSD17B10
SCHEMBL4482511 0.70 CRHR1 (0.46) CRHR1CDC7DBF4
SCHEMBL4495086 0.69 CRHR1 (0.49) CRHR1
SCHEMBL3146536 0.67 CRHR1 (0.81) CRHR1
SCHEMBL4499176 0.67 CRHR1 (0.46) CRHR1CDC7DBF4
SCHEMBL5848602 0.66 POLB (0.41) CRHR1KDM4ELMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090281120-A1 BICYCLIC HETEROCYCLIC COMPOUND ONO PHARMACEUTICAL CO., LTD (JP) 2009-11-12 US disclosed
EP-1961745-A1 BICYCLIC HETEROCYCLIC COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2008-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281120-A1 BICYCLIC HETEROCYCLIC COMPOUND CRHR1, NR3C1, CNR1 CRHR1 1/4885KDM4E 3295/4885LMNA 3836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.